Application of human interleukin-24 gene recombined vector mediated by adenovirus in preparing tumor analgesic medicament

Abstract

The invention discloses application of human interleukin-24 gene recombined vector mediated by adenovirus in preparing a tumor analgesic medicament. The technical proposal comprises the following stepThe invention discloses application of human interleukin-24 gene recombined vector mediated by adenovirus in preparing a tumor analgesic medicament. The technical proposal comprises the following steps: (1) constructing recombinant transfer plasmid pAdTrack-CMV-IL-24; (2) preparing positive cloning pAdEasy-l-pAdTrack-CMV-IL-24 by the pAd-TrackhCMV-IL-24 with correct order-checking according to a cs: (1) constructing recombinant transfer plasmid pAdTrack-CMV-IL-24; (2) preparing positive cloning pAdEasy-l-pAdTrack-CMV-IL-24 by the pAd-TrackhCMV-IL-24 with correct order-checking according to a conventional method; (3) carrying out virus packaging on the pAdEasy-l-pAdTrack-CMV-IL-24 gene recombinant plasmid, and obtaining high-titre recombinant adenovirion (Ad-IL-24) after multiple amplificatonventional method; (3) carrying out virus packaging on the pAdEasy-l-pAdTrack-CMV-IL-24 gene recombinant plasmid, and obtaining high-titre recombinant adenovirion (Ad-IL-24) after multiple amplifications; and (4) infecting a tumor tissue by the Ad-IL-24. The technical proposal is combined with an analgesia test of a rat tibia cancer pain model, and results not only prove that the Ad-24 has consenions; and (4) infecting a tumor tissue by the Ad-IL-24. The technical proposal is combined with an analgesia test of a rat tibia cancer pain model, and results not only prove that the Ad-24 has consensual carcinostatic function, but also prove that expression of the adenovirion interleukin-24gene in a cell can play a role in inhibiting cancer pains in multiple ways.sual carcinostatic function, but also prove that expression of the adenovirion interleukin-24gene in a cell can play a role in inhibiting cancer pains in multiple ways.

Description

technical field [0001] The invention relates to a new application of the adenovirus-mediated interleukin-24 gene, in particular to the application of the adenovirus-mediated interleukin-24 gene in the field of analgesia. Background technique [0002] In recent years, the incidence of cancer has been increasing year by year. According to WHO statistics, there are more than 10 million new cancer patients in the world every year, of which 30-50% are accompanied by different degrees of cancer pain. Alleviating or controlling cancer pain has become the key to alleviating the suffering of patients and improving the quality of life. One of the key points of work. In recent years, with the continuous improvement of animal models of cancer pain, the research on the mechanism of cancer pain has become more and more perfect, and the treatment of cancer pain has also achieved good development. [0003] 1. Research has found that the main mechanisms of cancer pain are as follows: [00...

AI Technical Summary

Problems solved by technology

[0019] The reports on adenovirus-mediated interleukin-24 (Ad-IL-24) mainly focus on its application in suppressing tumors. In recent years, a large number of foreign research data have proved that Ad-IL-24 can inhibit tumor growth and promote apoptosis. Ad-IL-24 can regulate the secretion of IL-6, TNF-α, IFN-γ and other cytokines; members of our research group have done a lot of research on this in China, and the results show that Ad-IL-24 has specific anti-tumor Ad-IL-24 has no harmful effect on normal cells; in the United States, Ad-IL-24 has entered the phase I clinical trial of tumor gene therapy; however, the therapeutic effect of Ad-IL-24 on cancer pain has not been reported at home and abroad.

There is no report about its application in tumor analgesia

Images